191 related articles for article (PubMed ID: 35580504)
1. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
Ghanem I; Lora D; Herradón N; de Velasco G; Carretero-González A; Jiménez-Varas MÁ; Vázquez de Parga P; Feliu J
ESMO Open; 2022 Jun; 7(3):100485. PubMed ID: 35580504
[TBL] [Abstract][Full Text] [Related]
2. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials.
Uson Junior PLS; Dias E Silva D; de Castro NM; da Silva Victor E; Rother ET; Araújo SEA; Borad MJ; Moura F
ESMO Open; 2023 Feb; 8(1):100771. PubMed ID: 36638709
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
4. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
6. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang B; Chen K; Liu W; Long D; Wang Y; Liu X; Ma Y; Tian X; Yang Y
Clin Exp Med; 2023 Nov; 23(7):3159-3169. PubMed ID: 37310659
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
8. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
Front Oncol; 2021; 11():812102. PubMed ID: 35083158
[TBL] [Abstract][Full Text] [Related]
10. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
Liu S; Li H; Xue Y; Yang L
PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
[TBL] [Abstract][Full Text] [Related]
12. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.
Yang SQ; Zou RQ; Dai YS; Li FY; Hu HJ
Updates Surg; 2024 Jan; 76(1):1-15. PubMed ID: 37639177
[TBL] [Abstract][Full Text] [Related]
14. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.
Ye M; Zhang Q; Chen Y; Fu Q; Li X; Bai X; Liang T
HPB (Oxford); 2020 Jun; 22(6):821-832. PubMed ID: 32001139
[TBL] [Abstract][Full Text] [Related]
16. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Janssen QP; van Dam JL; Kivits IG; Besselink MG; van Eijck CHJ; Homs MYV; Nuyttens JJME; Qi H; van Santvoort HJ; Wei AC; de Wilde RF; Wilmink JW; van Tienhoven G; Groot Koerkamp B
Ann Surg Oncol; 2021 Dec; 28(13):8297-8308. PubMed ID: 34142290
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
18. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials.
Lim Khai Shin A; Ho Si Ying A; Neo Hui Wen S; Yeo SC; Tay KV
J Gastrointest Surg; 2023 Jun; 27(6):1261-1276. PubMed ID: 36882627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
